TSX:RVX - Toronto Stock Exchange - CA76128M1086 - Common Stock - Currency: CAD
TSX:RVX (7/23/2025, 7:00:00 PM)
0.21
-0.02 (-6.67%)
The current stock price of RVX.CA is 0.21 CAD. In the past month the price increased by 425%. In the past year, price increased by 320%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 324.26M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 252.08M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 225.56M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 196.79M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 143.00M | ||
WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 119.59M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 77.13M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 70.87M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 19.46 | 69.37M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 56.19M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 45.90M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 29.5 | 41.47M |
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 18 full-time employees. The company went IPO on 2001-10-12. The firm is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The firm's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The company partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
RESVERLOGIX CORP
300-4820 Richard Rd SW
Calgary ALBERTA T3E 6L1 CA
CEO: Donald J. McCaffrey
Employees: 18
Phone: 14032549252
The current stock price of RVX.CA is 0.21 CAD. The price decreased by -6.67% in the last trading session.
The exchange symbol of RESVERLOGIX CORP is RVX and it is listed on the Toronto Stock Exchange exchange.
RVX.CA stock is listed on the Toronto Stock Exchange exchange.
RESVERLOGIX CORP (RVX.CA) has a market capitalization of 59.71M CAD. This makes RVX.CA a Micro Cap stock.
RESVERLOGIX CORP (RVX.CA) currently has 18 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RVX.CA does not pay a dividend.
RESVERLOGIX CORP (RVX.CA) will report earnings on 2025-08-12.
RESVERLOGIX CORP (RVX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.07).
ChartMill assigns a technical rating of 8 / 10 to RVX.CA. When comparing the yearly performance of all stocks, RVX.CA is one of the better performing stocks in the market, outperforming 99.4% of all stocks.
Over the last trailing twelve months RVX.CA reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS decreased by -30.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -181.84% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to RVX.CA. The Buy consensus is the average rating of analysts ratings from 5 analysts.